Effects of Sacubitril/Valsartan combined with Amlodipine in treatment of elderly patients with coronary heart disease complicated with heart failure
Objective:To observe effects of Sacubitril/Valsartan combined with Amlodipine in treatment of elderly patients with coronary heart disease complicated with heart failure.Methods:The clinical data of 76 elderly patients with coronary heart disease complicated with heart failure admitted to the hospital from December 2022 to December 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and study group,38 cases in each group.Both groups were given conventional anti-heart failure treatment.On this basis,the control group was treated with Amlodipine,while the study group was treated with Sacubitril/Valsartan on the basis of that of the control group.Both groups were treated for 2 months.The clinical efficacy,the levels of cardiac function indexes[left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),stroke volume(SV)],the levels of inflammatory factors[interleukin(IL)-6,IL-4,tumor necrosis factor-α(TNF-α)],the 6-min walking distance,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of treatment in the study group was 94.74%(36/38),which was higher than 71.05%(27/38)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of LVESD and LVEDD in the study group were lower than those in the control group,the levels of LVEF and SV were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of IL-6,IL-4 and TNF-α in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the 6-min walking distance of the study group was longer than that of the control group,and the difference was statistically significant(P<0.05).However,there were no obvious adverse reactions in the two groups during the treatment.Conclusions:Sacubitril/Valsartan combined with Amlodipine in the treatment of the elderly patients with coronary heart disease and heart failure can improve the total effective rate of treatment,improve the levels of cardiac function indexes,reduce the levels of inflammatory factors,and enhance sports endurance.Moreover,it is superior to single Amlodipine treatment.
ElderlyCoronary heart diseaseHeart failureSacubitril/ValsartanAmlodipineCardiac function
NETL
NSTL
万方数据
